RepliCel Life Sciences Inc.

08/06/2022

DermaPrecise Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections.

Independent Testing Performed by Innovacell Demonstrates the DermaPrecise™ Control Leads to Unparalleled Post-Injection Cell Survival and Viability Consistency.

https://www.accesswire.com/viewarticle.aspx?id=710326

"What is exciting about the results of the recent study done at Monasterium Laboratory, when combined with the results of this Innovacell study, is that we are now clearly showing the ability to consistently inject a 100μL volume using a 9-needle head in a 1cm2 array at 8mm maximum needle travel with the injection performed during needle withdrawal and, as per the image attached to this release demonstrates, ensure deposition in the mid-to-lower dermis and upper subcutaneous fat layer, at depths consistent with the location of hair follicle bulbs in androgenetic alopecia affected scalp. We believe this will be enormously valuable to our RCH-01 program by eliminating two important variables which are known to be linked to the success of clinical outcomes," states RepliCel President and CEO, R. Lee Buckler.

07/28/2022

RepliCel’s Manufacturing Inspected by Japan’s PMDA.

https://www.accesswire.com/viewarticle.aspx?id=709735

After over a year of pandemic-related delays, Japan's PMDA, attended at the Company's contract mfg facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell therapy products.

This inspection was an important prerequisite to accelerating RCS-01 and RCT-01 clinical studies, partnership deals, and commercialization in Japan. We await formal manufacturing certification.

After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell therapy products VANCOUVER, BC / ACCESSWIRE / July 28, 2022 / RepliCel Life Sciences Inc. (OTCPINK...

07/28/2022

Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing.

Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue

After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell therapy products VANCOUVER, BC / ACCESSWIRE / July 28, 2022 / RepliCel Life Sciences Inc. (OTCPINK...

02/28/2022

Delighted to share this interview and to be part of the exciting and democratizing bio-partnering platform BioNeex has built and is now experiencing explosive growth!

RepliCel Life Science is a Vancouver based biotech company focused on aesthetics and orthopedics, developing tailor-made products to restore cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. RepliCel’s cell therapy product candidate pipeline is comprised o...

01/10/2022

RepliCel announces a new patent application and patents granted. The new patent app covers new commercial embodiments of technologies in DermaPrecise™ and one of the new patents granted was in Japan related to RCT-01 cell therapy for tendinopathy.

New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key marketsVANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next...

12/21/2021

We have now taken the step to terminate Shiseido's license to RCH-01 (something Shiseido alleges they did in 2016). In the context of the ongoing arbitration proceedings, this provides RepliCel with the widest array of potential remedies. Nothing prevents the parties from settling this dispute any time.

This is just another step in our pursuit of a resolution to this dispute in < 1 yr. RepliCel's Board and legal team remain very confident of the strength of our case. We also strongly believe in an outcome which translates into significant positive impact on RepliCel's valuation.

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today that the dispute between Shiseido and RepliCel has led to t...

12/17/2021

The extracellular matrix under skin loses ~1% of its collagen per year. By age 45, we face ~25% collagen loss causing a loss of skin support structure and elasticity.

RCS-01 is in development to reverse this collagen loss, stimulate new collagen production, and regenerate the thickness and elasticity of the extracellular matrix thus improving the skin's appearance and minimizing fine wrinkles, all using a patient's own cells.

11/26/2021

We are very proud of the work we are doing with Mohsen Akbari at University of Victoria partially funded by Canada's Natural Sciences and Engineering Research Council of Canada (NSERC) and Mitacs and always nice to see it profiled as it is here. Thanks to all involved!

https://www.uvic.ca/ecs/about/newsletters/2021fall/02-cell.php

"The ultimate goal is to commercialize the technology, so that a biopsy taken, for example, from a patient's skull or shoulder, which might harvest only 10,000 cells, could be grown in the lab to a billion or more cells. These cells could then be reinjected into the patient to treat a wide range of health and aesthetic conditions."

Biomedical engineer Mohsen Akbari has devised an ingenious way to exponentially replicate human cells in the lab without harmful chemicals & #8211; a key step in a BC biotech company& #8217;s pl...

11/11/2021

RepliCel has shipped DermaPrecise (tm) injector prototypes and consumables to an independent laboratory for clinical simulation testing in various types of donated human skin tissue.

https://www.biospace.com/article/releases/replicel-ships-dermaprecise-tm-injector-prototypes-and-consumables-to-independent-laboratory-for-clinical-simulation-testing/

11/09/2021

RepliCel's clinical team moves forward preparations for the next-phase study of its RCS-01 cell therapy for treatment of aging and sun-damaged skin in Japan.

accesswire.com/671715/RepliCels-Clinical-Advisory-Team-Delivers-Skin-Rejuvenation-Clinical-Study-Synopsis-to-its-Japanese-Regulatory-and-Clinical-Study-Management-Team

11/05/2021

Our AGM will be held November 30 at 11am Pacific. Shareholders should watch for materials which have now been disseminated. In-person attendance may be limited due to COVID protocols - online attendance is encouraged. $RP.V

Further details and materials: https://www.replicel.com/About/fact-sheets